Early MS treatments impact relapses and brain scarring differently, but not disability
A study published in Neurology Open Access indicates that B-cell-depleting therapies are more effective at reducing relapses and brain scarring in early-stage MS patients compared to standard pills. However, the study found no significant difference in disability progression between the treatment groups after two years.
Why it matters
Informs clinical decision-making for newly diagnosed MS patients by comparing the efficacy of different treatment pathways.
edited by Sadie Harley , reviewed by Alexander Pol
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Olga Yastremska, New Africa, Africa Studio Therapy targeting the immune system's B cells might offer better odds against relapses in the early stages of multiple sclerosis (MS), a new study reports. People taking IV drugs that lower immune B-cell levels had a 62% lower rate of relapse than those taking pills frequently prescribed for early MS, the study team found.
The findings were published in the journal Neurology Open Access .
Patients were also less likely to develop brain scarring associated with MS if they started B-cell-depleting therapies slightly after their diagnosis, researchers said.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in